Inozyme Pharma, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Inozyme Pharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • Inozyme Pharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$24.6M, a 47.7% decline year-over-year.
  • Inozyme Pharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$96.5M, a 41.6% decline year-over-year.
  • Inozyme Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$71.2M, a 6.13% decline from 2022.
  • Inozyme Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$67.1M, a 18.4% decline from 2021.
  • Inozyme Pharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$56.6M, a 0.35% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$71.2M -$4.11M -6.13% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-12
2022 -$67.1M -$10.4M -18.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-12
2021 -$56.6M -$200K -0.35% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-22
2020 -$56.4M -$36.7M -186% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-15
2019 -$19.7M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.